Bryostatin 2

Bryostatin 2 is one of a series of cyclic macrolides isolated from the marine bryozoan Bugula neritina (Order Cheilostomata), and a potent modulator of Protein Kinase C (PKC).

Bryostatin 2 is a macrocyclic lactone with anti-tumor properties and a potent activator of Protein Kinase C (PKC), which inhibits the growth of A549 cells. Bryostatin 2 has been documented to compete with phorbol ester binding to PKC at a Ki= 3.4 nM, a Ki

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
Bryostatin 2, 10ug
10ug 1-2 weeks
Regular Price:$210.00
On Sale:
Bryostatin 2, 50ug
50ug 1-2 weeks
Regular Price:$820.00
On Sale:

Product Type: Small Molecule
Chemical Formula: C45H66O16
CAS number: 87745-28-6
Molecular Weight: 862.4
Format: White crystalline solid
Purity: >95 % determined by HPLC
Solubility: Soluble in methanol and ethanol
Stability: Stable as a solid over extended period at -20C.
Storage: -20C, avoid exposure to oxygen and direct sunlight
Shipped: Cold Pack


Bryostatin 2 HPLC Chromatogram.

Purification Notes: Purified using near-critical and supercritical fluids as an alternate to conventional organic solvents during a sequence of phase extraction and chromatographic purification steps.

  1. Castor T. (1995,1997). Method and Apparatus for Extracting Taxol from Source Materials. US Patent No. 5,440,055 and European Patent No. 689,537.
  2. Castor T. (1998). Method and Apparatus for Isolating Therapeutic Compositions from Source Materials. US Patent No. 5,750,709.
  3. Castor T. (2001). Supercritical Fluid Isolation of Bryostatin 1. SBIR Phase II Final Report. SBIR Grant No. 5 R44 CA 64017-03.
  4. Dale I, Bradshaw T, Gescher A and Pettit G. (1989). Comparison of effects of Bryostatin 1 and 2 and 12-O-Tetradecanoylphorbol-13-acetate on Protein Kinase C activity in A549 human lung carcinoma cells. Cancer Res. 49: 3242-3245.
  5. Davidson S, Allen S, Lim G, Anderson C and Haygood M. (2001). Evidence for the Biosynthesis of Bryostatins by the Bacterial Symbiont "Candidatus Endobugula sertula" of the Bryozoan Bugula neritina. Appl. Environ. Microbiol. 67, 4531-4537.
  6. Dell'Aquila M, Herald C, Kamano Y, Pettit G and Blumberg P. (1988). Differential effects of bryostatins and phorbol esters in arachidonic acid metabolite release and epidermal growth factor binding in C3H 10T½ Cells. Cancer Res. 48: 3702-3708.
  7. Jalava A, Heikkilä J, Akerlind G, Pettit G and Akerman K. (1990). Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells. Cancer Res. 50: 3422-3428.
  8. Pettit G. (1991). Synthetic conversion of Bryostatin 2 into Bryostatin 1. US Patent No. 5,072,004.
  9. Pettit G, Herald C, Kamano Y, Gust D and Aoy-agi R. (1983). The structure of Bryostatin 2 from the marine bryozoan Bugula neritina. J. Am. Chem. Soc. 104, 6846–6848.
  10. Schaufelberger D, Koleck M, Beutler J, Vatakis A, Alvarado A, Andrews P, Marzo L, Muschik G, Roach J, Ross J, Lebherz W, Reeves M, Eberwein R, Rodgers L, Testerman R, Snader K and Forenza S. (1991). The large scale isolation of Bryostatin 1 from Bugula neritina following good manufacturing practices. Journal of Natural Products. 54, 1265-1270.
  11. Trenn G, Pettit G, Takayama H, Hu-Li J and Sitkovsky M. (1988). Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins.

If you publish research with this product, please let us know so we can cite your paper.